Horizon Therapeutics (HZNP) Tops Q3 EPS by 77c, Raises FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Therapeutics (HZNP) PT Raised to $115 at Cowen Following Q3 Results
November 2, 2020 10:14 AM ESTCowen analyst Ken Cacciatore raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $115.00 (from $100.00) while maintaining an Outperform rating.
The analyst commented, "The Tepezza launch continues to reflect the rapid uptake and penetration in both acute and chronic TED patients, and this outperformance... More
